• About Us
    • Company Overview
    • Our History
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Our Advisors
  • Therapeutic Areas
    • Acute Myocarditis
    • Recurrent Pericarditis
    • Heart Failure
  • Research
    • R&D Partners
    • Our Science
    • Resources
  • Pipeline
  • CardiolRX™
  • Investors
    • Events & Presentations
    • Press Releases
    • Analyst Coverage
    • Stock Information
    • Filings & Financials
    • Corporate Governance
    • Contact Us
News

Cardiol Therapeutics Announces Study Results from Collaborating Research Center Demonstrating Cardioprotective Effects of Cannabidiol in a Model of Heart Failure

March 07, 2023

Cardiol Therapeutics Announces First Patient Enrolled in Phase II Study Evaluating CardiolRx™ for the Treatment of Recurrent Pericarditis

January 17, 2023

Cardiol Therapeutics Commences Multi-center Phase II Pilot Study of CardiolRx™ for the Treatment of Recurrent Pericarditis

December 12, 2022

Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

November 14, 2022

Cardiol Therapeutics Announces Study Results Demonstrating Protective Effects of CardiolRx™ in a Model of Acute Pericarditis

November 07, 2022

Cardiol Therapeutics Prioritizes Phase II Clinical Programs in Underserved Heart Diseases

October 25, 2022

Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating CardiolRx™ Inhibits and also Promotes Reversal of Mechanisms Leading to Cardiac Fibrosis

October 03, 2022

Cardiol Therapeutics Announces Poster Presentation at The Annual Scientific Meeting of the Heart Failure Society of America

September 28, 2022

Cardiol Therapeutics Announces First Patient Enrolled in ARCHER, a Phase II Clinical Trial of CardiolRx™ for Treatment of Acute Myocarditis

August 03, 2022

Cardiol Therapeutics Reports Results of 2022 Annual General Meeting

June 29, 2022
Page 1 of 1112345...10...»Last »
  • About Us
  • Therapeutic Areas
  • Research
  • Pipeline
  • CardiolRX™
  • Investors
  • Contact

TSX:CRDL NASDAQ:CRDL

Sign up to receive the latest news from Cardiol Therapeutics

© 2023 Cardiol Therapeutics Inc. All rights reserved.      Terms of Use      Privacy Policy